

Lao People's Democratic Republic

Tuberculosis profile

Population 2017

6.9 million

Estimates of TB burden*, 2017	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	2.5 (1.5–3.8)	37 (22–56)
Mortality (HIV+TB only)	0.3 (0.19–0.43)	4.3 (2.7–6.3)
Incidence (includes HIV+TB)	12 (7.5–16)	168 (109–240)
Incidence (HIV+TB only)	0.68 (0.43–0.98)	9.9 (6.3–14)
Incidence (MDR/RR-TB)**	0.17 (0.07–0.31)	2.5 (1–4.5)

Estimated TB incidence by age and sex (thousands)*, 2017

	0-14 years	> 14 years	Total
Females	0.74 (0.67–0.81)	3 (2.4–3.6)	3.8 (2.9–4.6)
Males	0.82 (0.73–0.9)	7 (4.8–9.1)	7.8 (5.3–10)
Total	1.6 (1.3–1.8)	10 (6.4–14)	12 (7.5–16)

TB case notifications, 2017

Total cases notified	5 934
Total new and relapse	5 730
- % tested with rapid diagnostics at time of diagnosis	57%
- % with known HIV status	89%
- % pulmonary	93%
- % bacteriologically confirmed among pulmonary	73%

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2017	50% (35–77)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2017	0.25 (0.13–0.4)

TB/HIV care in new and relapse TB patients, 2017

	Number	(%)
Patients with known HIV-status who are HIV-positive	311	6%
- on antiretroviral therapy		

Drug-resistant TB care, 2017	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			76 (34–120)
Estimated % of TB cases with MDR/RR-TB	1.2% (0.5–2)	4.1% (0–9.6)	
% notified tested for rifampicin resistance	56%	36%	3 256
MDR/RR-TB cases tested for resistance to second-line drugs			15
Laboratory-confirmed cases		MDR/RR-TB: 38, XDR-TB: 0	
Patients started on treatment ****		MDR/RR-TB: 34, XDR-TB: 0	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2016	86%	4 976
Previously treated cases, excluding relapse, registered in 2016	80%	189
HIV-positive TB cases registered in 2016	73%	225
MDR/RR-TB cases started on second-line treatment in 2015	84%	32
XDR-TB cases started on second-line treatment in 2015		0

TB preventive treatment, 2017

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	29% (27–32)

TB financing, 2018

National TB budget (US\$ millions)	3.7
Funding source: 10% domestic, 81% international, 8% unfunded	


* Ranges represent uncertainty intervals

** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history


**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence
— Notified (new and relapse)
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2017




■ Females ■ Males □ Incidence

Treatment success rate (%)



— New and relapse
— Retreatment, excluding relapse
— HIV-positive — MDR/RR-TB — XDR-TB

Total budget (US\$ millions)



■ Unfunded
■ Funded internationally
■ Funded domestically